Literature DB >> 7981173

Multiple organ dysfunction syndrome (MODS) following multiple trauma: rationale and concept of therapeutic approach.

W Ertel1, H P Friedl, O Trentz.   

Abstract

The multiple organ dysfunction syndrome (MODS) represents the number one cause of death in surgical intensive care units. It is divided into a primary and a secondary MODS based on time of manifestation and pathophysiologic events which attribute to it. The therapy of the primary MODS includes sufficient and quick resuscitation, adequate oxygen delivery and early enteral nutrition to reduce or avoid the incidence of bacterial translocation. In addition, a reduction of the "antigenic load" by control of hemorrhage, radical wound debridement, decompression, and fixation of long bone fractures appears to be effective in reducing the occurrence of MODS. The treatment of the secondary MODS remains supportive and its prevention is essential. Further studies are necessary to evaluate the clinical significance of new therapeutic agents such as monoclonal antibodies or cytokine receptor antagonists.

Entities:  

Mesh:

Year:  1994        PMID: 7981173     DOI: 10.1055/s-2008-1066112

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  3 in total

1.  Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection.

Authors:  D J Wickel; W G Cheadle; M A Mercer-Jones; R N Garrison
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

2.  Acute management and outcome of multiple trauma patients with pelvic disruptions.

Authors:  Markus Burkhardt; Ulrike Nienaber; Antonius Pizanis; Marc Maegele; Ulf Culemann; Bertil Bouillon; Sascha Flohé; Tim Pohlemann; Thomas Paffrath
Journal:  Crit Care       Date:  2012-08-22       Impact factor: 9.097

Review 3.  Current concepts, which effect outcome following major hemorrhage.

Authors:  David W Shields; Timothy P Crowley
Journal:  J Emerg Trauma Shock       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.